On November 21-22, 2023, the Berlin E-Forum was held in Berlin, Germany. The forum brings together experts in the fields of cancer risk, early detection, prevention, molecular diagnostics and data science to share groundbreaking research and progress in the field, and explore the challenges and opportunities of emerging technologies for early cancer detection. HymonBio was invited to this conference and discuss development trends of cancer early detection technology face-to-face with experts.
The forum focuses on early diagnosis and screening of tumors, as well as tumor gene detection technologies. The attending experts discussed the research and development status and future directions of various types of tumor detection technologies, as well as the latest trends in molecular diagnosis and the application of innovative data science in cancer medical research.
HymonBio introduced guests to the company’s technological achievements in early screening. With our unique nucleic acid extraction technology and MoLock, HymonBio has received recognition and attention from attending experts.
HymonBio Co., Ltd. was founded in 2015 and focuses on development, production, and sales of precision medicine-related products. The company adheres to technological innovation, and has applied for 36 patents, obtained 6 authorized patents, 11 products have obtained the Chinese medical device certificate, 59 products have obtained EU CE certificates, and 1 product has obtained US FDA EUA and passed the ISO 13485 certificate system. The company has been awarded honors such as High-Tech Enterprise, Jiangsu Provincial R&D Enterprise (the first in various counties and cities in Suzhou), Jiangsu Private Science and Technology Enterprise, Jiangsu Province “Double Innovation Plan” Supporting Enterprise, and Gusu Innovation and Entrepreneurship Leading Talent Enterprise.
Post time: Nov-23-2023